Skip to main content
. Author manuscript; available in PMC: 2025 Aug 1.
Published in final edited form as: Transfusion. 2024 Jun 17;64(8):1469–1480. doi: 10.1111/trf.17922

Figure 1. Testosterone therapy (TT)-related changes in RBC susceptibility to oxidative hemolysis and methemoglobin concentration.

Figure 1.

Data derived from 8 individuals before and after testosterone replacement therapy (TT) initiation. TT-1, TT-2, and TT-3, 1–2 months, 5–6 months, and 10–12 months after TT initiation (Pre-TT). N=7–8. A. Percent oxidative hemolysis on each visit. *, p<0.05 compared with Pre-TT. B-C. Pearson correlation analyses between individuals’ plasma free testosterone (B) and percent oxidative hemolysis. r, Pearson correlation coefficient. C. Percent methemoglobin on each visit. ***, p=0.0007 compared with Pre-TT. D. Pearson correlation analyses between individuals’ plasma free testosterone and percent methemoglobin. A and C, before-after plots. Each symbol represents a unique individual.